Industry/FDA Line Extension Studies Suggested By OTC Division’s Rosebraugh
This article was originally published in The Tan Sheet
Executive Summary
The industry should partner with the FDA on studies evaluating whether OTC drug line extensions create consumer confusion, according to OTC Division Deputy Director Curtis Rosebraugh, MD